The Personal Care Products Council and Consumer Healthcare Products Association submitted comments to the U.S. Food & Drug Administration (FDA) in response to the Sunscreen Tentative Final Monograph.
The 2018 results from the National Institute on Drug Abuse and University of Michigan's annual drug abuse survey, Monitoring the Future, show that the percentage of teens using OTC cough medicine containing dextromethorphan to get high remains at three percent.
New members of the Consumer Healthcare Products Association (CHPA) Board of Directors were elected at the association’s fall meeting, held November 14, 2018, in New York City, N.Y.
Yesterday, Pennsylvania Governor Tom Wolf signed into law HB 1951, legislation prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors.
In a study newly published in the medical journal Clinical Toxicology, “therapeutic misuse” of OTC combination products containing acetaminophen was infrequent and declined over a 10-year period.
Today, the Consumer Healthcare Products Association (CHPA) issued the following statement upon submitting comments to the Food and Drug Administration (FDA) regarding its draft guidance titled, “Innovative Approaches for Nonprescription Drug Products.”
The dietary supplement industry’s self-regulatory coalition, the SIDI Work Group, today released an updated version of the Standardized Information on Dietary Ingredients (SIDI TM) Protocol.
CHPA applauds Colorado for enacting a law prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors this week.
CHPA applauds the House of Representatives’ passage of legislation that will restore consumers’ ability to use their HSAs and FSAs to purchase over-the-counter medicines and feminine hygiene products.
CHPA is pleased to see FDA’s long-awaited draft guidance on innovative approaches for greater consumer access to nonprescription medicines, and applauds FDA’s focus on patient safety as a top priority.
CHPA is pleased to see FDA’s long-awaited draft guidance on innovative approaches for greater consumer access to nonprescription medicines, and applauds FDA’s focus on patient safety as a top priority.